Technical Analysis for AYTUZ - Aytu Bioscience Inc Wt Exp 11/02/2021

Grade Last Price % Change Price Change
grade F 0.0051 0.00% 0.0000
AYTUZ closed unchanged on Friday, August 23, 2019, on approximately normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A Down Down
See historical AYTUZ trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Wide Bands Range Expansion 0.00%
Gapped Down Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Narrow Range Bar Range Contraction -27.14%
Stochastic Reached Oversold Weakness -27.14%
Inside Day Range Contraction -27.14%
Wide Bands Range Expansion -27.14%

Older signals for AYTUZ ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Aytu is a commercial-stage specialty pharmaceutical company focused on global commercialization of novel products in the field of urology. We are currently focused on addressing significant medical needs in the areas of hypogonadism, urological cancers, urinary tract infections and male infertility. We currently market Natesto (testosterone) nasal gel, a novel formulation of testosterone delivered via a discreet, easy-to-use nasal gel. Natesto is approved by the U.S. Food and Drug Administration, or FDA, for the treatment of hypogonadism (low testosterone) in men and is the only testosterone replacement therapy, or TRT, delivered via a nasal gel. Natesto offers multiple advantages over currently available TRTs and competes in a $2.4 billion market. We also currently market ProstaScint (capromab pendetide), the only radioimaging agent indicated to detect the prostate specific membrane antigen, or PSMA, in the assessment and staging of prostate cancer. We also market Primsol (trimethoprim hydrochloride) — the only FDA-approved trimethoprim-only oral solution for urinary tract infections. We have a focused pipeline, including MiOXSYSTM, a novel in vitro diagnostic device that is currently CE marked (which generally enables it to be sold within the European Economic Area and for which we intend to initiate a final clinical study to enable FDA clearance in the U.S.
Medicine RTT Pharmaceutical Organ Systems Alcohols Prostate Cancer Hormones Ketones Urinary Tract Infections Testosterone Androstanes Urinary Tract Infection U.S. Food And Drug Administration Hypogonadism In Vitro Diagnostic Device Testosterone Replacement Therapy Androgen Replacement Therapy Indium (111in) Capromab Pendetide Male Infertility Trimethoprim Only Oral Solution Urological Cancers
Is AYTUZ a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Indicator Value
52 Week High 0.41
52 Week Low 0.0007
Average Volume 55,816
200-Day Moving Average 0.0
50-Day Moving Average 0.0101
20-Day Moving Average 0.01
10-Day Moving Average 0.0081
Average True Range 0.0029
ADX 15.87
+DI 36.1179
-DI 41.5233
Chandelier Exit (Long, 3 ATRs ) 0.0083
Chandelier Exit (Short, 3 ATRs ) 0.0138
Upper Bollinger Band 0.0162
Lower Bollinger Band 0.0038
Percent B (%b) 0.1
BandWidth 124.0
MACD Line -0.0015
MACD Signal Line -0.0009
MACD Histogram -0.0006
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.0051
Resistance 3 (R3) 0.0051 0.0051 0.0051
Resistance 2 (R2) 0.0051 0.0051 0.0051 0.0051
Resistance 1 (R1) 0.0051 0.0051 0.0051 0.0051 0.0051
Pivot Point 0.0051 0.0051 0.0051 0.0051 0.0051
Support 1 (S1) 0.0051 0.0051 0.0051 0.0051 0.0051
Support 2 (S2) 0.0051 0.0051 0.0051 0.0051
Support 3 (S3) 0.0051 0.0051 0.0051
Support 4 (S4) 0.0051